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ABSTRACT
Salivary adenoid cystic carcinoma (SACC) is characterized by invasive local 
growth and a high incidence of lung metastasis. Patients with lung metastasis have a 
poor prognosis. Treatment of metastatic SACC has been unsuccessful, largely due to a 
lack of specific targets for the metastatic cells. In this study, we showed that epidermal 
growth factor receptors (EGFR) were constitutively activated in metastatic lung 
subtypes of SACC cells, and that this activation was induced by autocrine expression 
of epiregulin (EREG), a ligand of EGFR. Autocrine EREG expression was increased in 
metastatic SACC-LM cells compared to that in non-metastatic parental SACC cells. 
Importantly, EREG-neutralizing antibody, but not normal IgG, blocked the autocrine 
EREG-induced EGFR phosphorylation and the migration of SACC cells, suggesting 
that EREG-induced EGFR activation is essential for induction of cell migration and 
invasion by SACC cells. Moreover, EREG-activated EGFR stabilized Snail and Slug, 
which promoted EMT and metastatic features in SACC cells. Of note, targeting EGFR 
with inhibitors significantly suppressed both the motility of SACC cells in vitro and 
lung metastasis in vivo. Finally, elevated EREG expression showed a strong correlation 
with poor prognosis in head and neck cancer. Thus, targeting the EREG-EGFR-Snail/
Slug axis represents a novel strategy for the treatment of metastatic SACC even no 
genetic EGFR mutation.
INTRODUCTION
Salivary adenoid cystic carcinoma (SACC) is a 
common subtype of malignant salivary gland tumors 
in head and neck, accounting for approximately 10% 
of salivary gland tumors and about 25% of malignant 
salivary gland tumors [1]. Clinical studies indicate that 
SACC is characterized by invasive local growth and 
a high incidence of distant metastasis [2]. Although 
SACC can metastasize to multiple organs including 
bone, liver, and cerebrum, the lung is the predominant 
anatomical site of distant metastasis [3]. Lung metastasis 
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is also a poor prognostic factor for patients with SACC. 
Patients without distant metastasis have overall 5-, 10-, 
and 20-year survival rates of 85.6%, 67.4%, and 50.4%, 
respectively, whereas the survival rates for patients 
with distant metastasis are 69.1%, 45.7%, and 14.3%, 
respectively [4]. To date, treatment for lung metastases has 
been unsuccessful, mainly due to a lack of specific targets 
for the metastatic cancer cells. Thus, an understanding of 
the mechanisms that govern lung metastasis in SACC is 
necessary for development of novel targeting strategies 
and improve patient survival. 
Cancer metastasis consists of at least four distinct 
steps: invasion, intravasation, extravasation, and metastatic 
colonization [5, 6]. The first step, the acquisition of 
invasive capability and motility, is the rate-limiting step 
in the metastatic cascade [7].  Epithelial-mesenchymal 
transition (EMT) is a process vital for morphogenesis 
during embryonic development, and is also critically 
important for metastasis [8]. A hallmark of EMT is the 
loss of E-cadherin expression [9]. Several transcription 
factors are implicated in the transcriptional repression of 
E-cadherin, including the zinc finger proteins of Snail, 
Slug, Twist, δEF1/ZEB1, SIP1, and E12/E47 [10–17]. 
EMT is also a dynamic and reversible process, provoked 
by signals, such as TGF-β, Wnt and TNF-α, from the 
microenvironment [18–22]. However, the cellular source 
of signals that control the EMT cascade in specific cancers 
are not completely understood.  
Aberrant activation of EGFR is involved in tumor 
development and progression for many cancers. Activation 
of EGFR can result from genetic mutation and gene 
amplification. Epiregulin (EREG) functions as a ligand 
of the EGF receptors EGFR/HER1 and HER4. EREG 
binds directly to EGFR and HER4 to induce tyrosine 
phosphorylation (activation) of EGFR, HER2, HER3 and 
HER4 [23, 24]. EGFR ligands implicated in human cancers, 
include EGF, EREG, amphiregulin (AREG), heparin-
bound EGF (HB-EGF) and transforming growth factor 
alpha (TGFα) [25]. The EGF ligand family participates in 
tumor proliferation, migration, invasion and angiogenesis. 
For example, EGF secreted by endothelial cells can 
promote cancer metastasis by inducing EMT in head and 
neck cancers [26]. EREG stimulates the proliferation 
of fibroblasts, hepatocytes, smooth muscle cells and 
keratinocytes, but inhibits the growth of several tumor-
derived cell lines [27, 28]. Many studies show that EREG 
expression correlated with cancer metastasis and could 
serve as a prognostic marker for cancers such as breast, 
colorectal, bladder and oral cancers [29–31]. However, 
the cellular source of EREG and the mechanism by which 
EREG promotes cancer metastasis are still unclear. 
We hypothesize that EMT plays an important role 
in the metastasis of SACC. In this study, we used two 
homologous SACC cell lines, SACC-83 and SACC-LM, 
to characterize the metastatic features of SACC [32]. The 
parental cell line, SACC-83 with a low lung metastasis 
rate, was isolated from a patient diagnosed pathologically 
with SACC in the sublingual gland. The daughter cell 
line SACC-LM, which has a high lung metastatic rate, 
originated from a murine lung metastatic lesion after 
a 5 round selection process, starting from intravenous 
injection of SACC-83 cells [32]. With these two SACC 
lines, we found that autocrine EREG-induced EGFR 
activation promotes lung metastasis via EMT. Moreover, 
upregulated EREG is prevalent in head and neck cancer 
and correlates with poor survival.
RESULTS
Lung metastatic SACC cells exhibit EMT-like 
characteristics 
To investigate the mechanisms that underlie lung 
SACC metastasis, we selected SACC-83 and SACC-LM as 
a pair of cell lines for characterization. First, we examined 
an EMT-related function, the migration capability of 
SACC-83 and SACC-LM cells, using the transwell and 
wound-healing assays. The transwell analysis showed that 
SACC-LM cells were much more motile and invasive 
than SACC-83 cells (Figure 1A–1B) in vitro and in areas 
of healing (Figure 1C–1D). In culture, SACC-83 cells 
exhibited the typical polygonal morphology of epithelial 
cells (Figure 1E), and immunofluorescence analysis 
revealed high levels of the epithelial marker E-cadherin 
and low levels of mesenchymal markers, N-cadherin and 
vimentin, as indicated. In contrast, SACC-LM cells were 
scattered, displayed a fibroblast-like morphology, with 
low levels of E-cadherin and high levels of N-cadherin 
and vimentin (Figure 1E). Immunoblot analysis confirmed 
the molecular features of these two cell lines (Figure 1F). 
Consistently, SACC-LM cells showed increased 
expression of Snail and Slug and repressed expression of 
E-cadherin (Figure 1F). Taken together, these data indicate 
that SACC-LM cells exhibited increased EMT-like 
characteristics compared to SACC-83 cells. Thus, EMT 
may be involved in SACC-LM lung metastasis.
Autocrine EREG activates EGFR pathway in 
high metastatic SACC-LM cells
We assumed that differences in the signal transduction 
pathways of SACC subtypes were responsible for the lung-
metastatic potential seen in SACC-LM cells. The EGFR is 
overexpressed in a variety of epithelial tumors, including 
salivary SACC. Activation of EGFR is thought to regulate 
the processes of metastasis and cancer cell survival. We 
examined phosphorylation of EGFR pathway target proteins 
in SACC-83 and SACC-LM cells. The results showed 
that p-EGFRs (Y1068, Y1173, Y1045, Y845) were all 
significantly increased in SACC-LM compared to SACC-83 
(Figure 2A). Moreover, p-Akt, p-STAT3 and p-ERK were 
increased in SACC-LM compared to SACC-83 (Figure 2A). 
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Of note, the EGFRs in SACC-LM were auto-activated since 
no exogenous ligand was added.
To determine if the EGFR in SACC-LM are mutated, 
we investigated genetic mutations by sequencing exons 18, 
19, and 21 of the EGFR gene in both SACC-83 and SACC-
LM cells; no genetic mutations were found in EGFR gene 
in either of these cell lines (data not shown). In addition, the 
subcellular localization of the EGFR showed no significant 
difference between the two cell lines (Figure 2B). 
Next, we asked if the differential activation of EGFR 
in these two SACC cell lines was the result of different 
levels of EGFR ligands. Previous reports of transcriptomic 
microarray analysis by Hu et al. [9], and by Wang et al. [33] 
showed that mRNA expression of EREG was 4.55-fold 
and 9.8-fold higher in SACC-LM than that in SACC-83, 
as determined by the respective investigators (Figure 2C). 
EREG encodes epiregulin, a known EGFR ligand. Thus, 
we examined mRNA and protein levels of EREG in these 
two cell lines by RT-PCR and immunoblot analysis. EREG 
mRNA expression was significant higher in SACC-LM 
than in SACC-83 (Figure 2D). Thus, autocrine secretion 
of EREG may contribute to an auto-activation of EGFR in 
SACC-LM cells. To determine if other EGFR-ligands were 
involved in EGFR activation, we examined the expression 
of EGF, TGFα, heparin binding-EGF (HB- EGF) and 
AREG in these two cell lines. However, there was no 
difference in the mRNA expression levels between these 
two cell lines (Figure 2E). To determine the role of 
autocrine cytokines, we examined protein expression after 
incubation in serum-free medium. The p-EGFR level was 
transiently decreased at 0.5 hour after the medium change, 
likely the result of removal of autocrine factor(s) in the 
conditioned (old) medium (Figure 2F–2G). Moreover, 
EGFR phosphorylation increased 1.5 hours after the 
medium change, suggesting that newly produced autocrine 
cytokines are responsible for this response (Figure 2F– 2G). 
Importantly, a neutralizing anti-EREG antibody, but not 
normal Ig G, abrogated auto-phosphorylation of EGFR in 
SACC-LM cell (Figure 2H), which suggests that EGFR 
activation in SACC-LM cells is caused by the autocrine 
EREG. Thus, autocrine EREG likely contributes to the 
auto-activation of EGFR pathway in the highly metastatic 
SACC-LM cells.
EREG is critical for activation of EGFR 
pathway and migration of SACC cells
Next, we examined the effects of exogenous EREG 
on activation of EGFR and its downstream signaling 
targets, including ERK, Akt, and STAT3, in the SACC 
Figure 1: Lung metastatic SACC-LM cells exhibit EMT characteristics. (A) The transwell migration and invasion 
assays established the migration and invasion capability of SACC-83 and SACC-LM cells with representative images shown. Scale 
bar = 200 μm. (B) Graphic representation of the percent of migrated cells from 3 separate experiments (mean ± SD). * indicates a p < 0.05. 
(C) Representative images of wound healing for SACC-83 and SACC-LM cells. Scale bar = 200 μm. (D) The number of migrated cells 
within the areas of healing surpassing the red lines was determined, and each experiment was repeated 3 times. * indicates a p < 0.05. 
(E) Representative images of the morphology and staining for E-cadherin, N-cadherin and vimentin in SACC-83 and SACC-LM cells. 
Scale bar = 200 μm. (F) Western blot analysis of E-cadherin, N-cadherin, ZO-1, vimentin, Snail and Slug protein levels in SACC-83 and 
SACC-LM cell lines.
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cell lines. Treatment of SACC-83 cells with recombinant 
human epiregulin (rhEREG) resulted in phosphorylation 
of EGFR, ERK, Akt and STAT3 in a time- and dose-
dependent manner (Figure 3A–3B). Moreover, rhEREG 
treatment (50 ng/ml) significantly increased migration 
of SACC cells in the wound closure assay in vitro 
(Figure 3C). Importantly, a neutralizing anti-EREG 
antibody significantly inhibited wound closure whereas 
normal Ig G failed to do so (Figure 3F); this finding 
suggests that autocrine EREG is required for the migration 
activity of SACC-LM cells. Taken together, these results 
demonstrate that EREG plays a critical role in activation of 
the EGFR pathway and induction of SACC cell migration. 
EREG induces Snail and Slug protein 
stabilization
Snail and Slug are two major transcription factors 
that induce EMT and promote cancer metastasis. We next 
investigated whether Snail and/or Slug regulated EREG-
induced SACC migration. Immunoblot analysis showed 
that rhEREG treatment significantly increased Snail and 
Slug protein levels in SACC-83 cells (Figure 4A), whereas 
mRNA levels of Snail and Slug, assessed by RT-PCR, 
remained unchanged (Figure 4B). Immunofluorescence 
microscopy confirmed these findings as the staining 
intensities of Snail and Slug were dramatically increased 
in SACC-83 cells following EREG treatment (Figure 4C). 
Thus, our results suggest that EREG regulated Snail and 
Slug expression via a transcription-independent mechanism. 
The optimal experimental condition for stabilization of 
Snail and Slug was rhEREG treatment for about 2 hour 
(Figure 4E) and at concentration of 50 ng/ml (Figure 4D).
EGFR pathway is required for EREG-induced 
stabilization of Snail and Slug 
Snail and Slug are labile proteins [34]. To 
determine the mechanism underlying the EREG-induced 
stabilization, we examined the protein levels of Snail 
and Slug in cells treated with or without rhEREG for 
various time (up to 4 hour) in absence or presence of 
protein translational inhibitor cycloheximide (CHX) 
(Figure 5A–5B). In cells treated with rhEREG, Snail 
and Slug were more stable than cells without treatment 
(Figure 5C–5D). These results suggest that rhEREG 
treatment promotes stabilization of Snail and Slug. To 
determine which signaling pathway is essential for EREG-
induced stabilization of Snail and Slug, we examined the 
effects of inhibitors of EGFR, Akt, STAT3, and ERK. 
Figure 2: Autocrine EREG secretion contributes to the auto-activation of EGFR in highly metastatic SACC. 
(A) Western blot analysis of p-EGFR, EGFR, p-AKT, AKT, p-STAT3, STAT3, p-ERK and ERK protein levels in SACC-83 and SACC-LM 
cell lines. (B) Immunofluorescence staining for EGFR is presented with DAPI (blue) nuclear staining. Scale bar = 200 μm. (C) Analysis of 
EREG mRNA levels with fold change in SACC-LM cells compared to SAC-83 cells using published chip assay data. (D) The mRNA and 
protein levels of EREG in SACC-83 and SACC-LM cell lines by RT-PCR and Western blot analysis, respectively. (E) The mRNA level of 
HB-EGF, TGF-α, AREG, EGF in SACC-83 and SACC-LM cell lines. (F) Western blot analyses of p-EGFR and EGFR from SACC-LM 
cells that were serum-starved as indicated. (G) Graphic representation of the ratio of p-EGFR and EGFR to GAPDH for indicated time 
points in SACC-LM cells. (H) Western blot analyses of p-EGFR in SACC-LM cells that were starved for 0.5h and then treated with EREG 
neutralizing antibody or with normal Ig G for 6 hours.
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The EGFR inhibitor erlotinib completely blocked EREG-
induced stabilization of Snail and Slug, whereas inhibitors 
of STAT3, ERK and PI3K showed partial inhibition 
(Figure 5E). Because STAT3, MAPK and PI3K are the 
major downstream targets of EGFR, these results strongly 
suggest that the activated EGFR pathway is crucial for 
EREG-induced stabilization of Snail and Slug.
Targeting EGFR suppressed migration and 
invasion of SACC-LM cells in vitro
Next, we examined the effects of targeting the EGFR 
on migration and invasion of SACC cells. Treatment of 
SACC-LM cells with erlotinib suppressed phosphorylated 
of the EGFR (Figure 6A), which correlated with decreased 
levels of vimentin and increased levels of E-cadherin 
(Figure 6B). Consistently, SACC-LM cell migration and 
invasion in the transwell assay were also dramatically 
suppressed by erlotinib treatment (Figure 6C–6D). Similarly, 
SACC-LM cell motility was also suppressed by erlotinib 
in wound healing assay (Figure 6E–6F). Taken together, 
these results demonstrate that the activated EGFR pathway 
is essential for the metastatic characteristics in SACC-LM 
cells, and that inhibition of EGFR function decreases the 
migration and invasion capabilities of these cells.
Targeting EGFR suppressed lung metastasis of 
SACC-LM in vivo
Next, we examined the effect of targeted inhibition 
of the EGFR in SACC-LM cells on metastasis to the 
lungs in vivo. SACC-LM were pretreated without or 
Figure 3: EREG activated EGFR/Akt/ERK/STAT3 pathways and promoted migration of SACC cells. (A) Western blot 
analyses for P-EGFR, EGFR, P-AKT, AKT, P-ERK, ERK, p-STAT3, STAT3 in SACC-83 cells treated with 0 to 1000 ng/mL rhEREG 
for 4 hours. (B) Western blot analyses for P-EGFR, EGFR, P-AKT, AKT, P-ERK, ERK, p-STAT3, STAT3 in SACC-83 cells treated with 
50 ng/mL rhEREG as indicated. (C) Representative images of migration by SACC-83 cells treated with or without rhEREG (50 ng/ml) for 
36 hours with representative images shown. Scale bar = 200 μm. (D) Graphic representation of the percent of migrated cells treated with 
rhEREG from 3 separate experiments as outlined in (C) with the mean ± SD indicated, *p < 0.05. (E) Representative images of migration 
by SACC-LM cells treated with EREG neutralizing antibody or with normal Ig G for 36 hours with representative images shown. Scale bar 
= 200 μm. (F) Graphic representation of the percent of migrated cells treated with EREG antibody from 3 separate experiments as outlined 
in (E) with the mean ± SD indicated, *p < 0.05.
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with erlotinib at 2 uM for 72 hours, and then i.v. injected 
into nude mice. Four weeks later, mice were sacrificed. 
The metastatic nodules in mouse lungs were counted, 
and the total area of all of the nodules in each section of 
the lung was calculated. Erlotinib pretreatment greatly 
reduced both the number of metastatic nodules and the 
area of lung metastases when compared to control group 
(Figure 7A– 7B). Thus, targeting EGFR significantly 
suppressed lung metastasis of SACC-LM in vivo.
To correlate the results from this study, we analyzed 
the clinical and molecular data of patients from the cancer 
genome atlas (TCGA). Because the survival data were not 
Figure 4: EREG induces protein stabilization of snail and slug. (A) Western blot analyses for Snail and Slug in SACC-83 cells 
treated with or without 50 ng/mL rhEREG for 4 hours. (B) RT-PCR analyses for mRNA levels of Snail and Slug. (C) Immunofluorescence 
staining for Snail and Slug in SACC-83 cells treated with or without 50 ng/mL rhEREG for 4 hours. Scale bar = 200 μm. (D) Western blot 
analyses for Snail and Slug from SACC-83 cells treated with 50 ng/mL rhEREG as indicated. (E) Western blot analyses for Snail and Slug 
from SACC-83 cells treated with 0 to 1000 ng/mL rhEREG for 4 hours.
Oncotarget25257www.impactjournals.com/oncotarget
available for patients with SACC in the TCGA cohort, we 
selected one independent study on head and neck cancer 
(TCGA, Nature 2015). We performed analysis by using 
the cBio Cancer Genomics Portal (http://cbioportal.org) 
[35]. Specifically, the expression levels of EREG gene 
were divided into two groups, high expression and low 
expression groups. By analysis of the overall survival 
based on EREG mRNA expression, we found that patients 
with high EREG levels had a significantly shorter median 
overall survival than patients with low EREG levels 
(Figure 7C). The median survival for patients with EREG 
alterations was 13.04 months and 26.41 for patients without 
alterations (Figure 7D). Thus, the results obtained both in 
experimental and clinical data showed that the EREG-
EGFR–Snail/Slug axis plays a critical role in controlling 
lung metastasis and in the prognosis of SACC patients.
DISCUSSION
In this study, we showed that the highly metastatic 
SACC-LM cells exhibited the EMT-like characteristics 
compared to the low-metastatic SACC-83 cells. The EMT-
like and metastatic features of SACC were promoted by 
autocrine EREG-activated EGFR signaling pathway. 
EREG-activated EGFR signaling stabilized Snail and Slug 
and induced EMT program in SACC-LM cells. Inhibition 
of EREG by neutralizing antibody abrogated EREG-
induced EMT features in SACC-LM cells. Thus, autocrine 
EREG-induced EGFR activation, even without a genetic 
mutation, in metastatic SACC patients may be suitable for 
EGFR targeting therapy. 
EGFR, a receptor tyrosine kinase, is important in 
controlling cell proliferation, motility, adhesion, invasion, 
angiogenesis and survival [36]. In fact, 85% of patients 
with SACC express the EGFR [37]. EREG is a ligand 
for the EGFR. Different from other members of the EGF 
family that are expressed ubiquitously in epithelium of 
normal tissues [38], EREG is predominantly expressed in 
the placenta and peripheral blood leucocytes. It has been 
reported that overexpression of EREG promotes migration 
and invasion of oral cancer cells in vitro. The effects of 
EREG are likely mediated by activation of ERK1/2, Akt, 
and Cox 2 [39]. Mechanistically, EREG activates not 
only homodimers of both ErbB1 and ErbB4 but also all 
possible heterodimeric ErbB complexes [23]. Thus, EREG 
may have important biological functions distinct from 
other EGFR ligands. 
Figure 5: EREG enhanced Snail and Slug stability require EGFR activation. (A–B) SACC-83 cells were treated with or 
without rhEREG for 2 hr, followed by incubation with cycloheximide (CHX; 10 μM) for an extended period of time. The levels of Snail 
and Slug were determined by Western blot analysis. (C–D) Graphic representation of densitometry results for Snail (C) and Slug (D) 
after cycloheximide treatment (circle, with rhEREG; square, without rhEREG). (E) Western blot analysis of Snail, Slug, P-EGFR, EGFR, 
P-AKT, AKT, P-ERK, ERK, p-STAT3, STAT3 from SACC-83 cells pretreated with various inhibitors for 1 hr followed by stimulation with 
rhEREG for 2 hr.
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Figure 6: Targeting EGFR inhibits the migration and invasion capabilities of SACC-LM cells. (A) Western blot analysis 
of p-EGFR and EGFR from SACC-LM cells treated with 0 to 20 uM erlotinib for 72 hours. (B) Western blot analysis of E-cadherin and 
vimentin levels from SACC-LM cells treated with 2 uM erlotinib for 72 hours. (C) Representative images of migration by SACC-LM cells 
treated with or without erlotinib (2 uM) for 24 hours. Scale bar = 200 μm. (D) Graphic representation of percent migrated cells from 3 
separate experiments with mean ± SD percent indicated. * indicates a p < 0.05. (E) Representative images of wound healing by SACC-LM 
cells treated with or without erlotinib (2 uM) for 24 hours. Scale bar = 200 μm. (F) Graphic representation of the number of migrated cells 
within the areas of healing surpassing the red lines from 3 separate experiments. * indicates a p < 0.05.
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Distant metastasis and EMT program in SACC has 
also been associated with c-kit, another receptor tyrosine 
kinase [40]. c-kit was shown to increase the CD133+/
CD44+ population in SACC [41].  And c-kit, along with 
Oct4, Nanog, SOX2, CD133, CD44, and ALDH1, has 
been considered as a cancer stem cell marker in primary 
non-small cell lung cancer (NSCLC), ovarian cancer 
and hepatocellular carcinoma [42]. Moreover, Slug was 
involved in the biologic activity of the SCF/c-kit signaling 
pathway [43] [44], and associated with an increased TNM 
stage, perineural invasion, local regional recurrence, and 
distant metastasis. However, targeting c-kit with inhibitors 
GISTs is not always effective in treating c-kit positive 
tumors [45]. This suggests that c-kit may not be the only 
or major molecule for mediating metastatic features, and 
other receptor tyrosine kinases may be involved in this 
metastatic process. Application of EGFR inhibitors, such 
as erlotinib and gefitinib, is a routine therapeutic targeting 
strategy for lung cancer patients with mutant EGFR, but 
not for those with wild-type EGFR. However, erlotinib 
appeared to be very effective in suppression of lung 
metastasis of SACC cells in vivo, as showed in this study. 
In support, some studies reported that gefitinib (Iressa), 
could stabilize 68% of SACC cases [46]. Although EGFR 
mutations in SACC [47, 48] are not as high as in lung 
cancer, the clinical effectiveness of targeting EGFR 
in SACC suggests that a different mechanism may be 
involved. Thus, targeting EGFR may be applicative for 
SACC patients with autocrine EREG, even no EGFR 
mutation. 
In summary, we demonstrate that autocrine EREG-
activated EGFR can stabilize Snail and Slug, induce 
EMT and metastatic features in SACC cells. Thus, the 
EREG-EGFR-Snail/Slug axis represents an important 
mechanism for SACC lung metastasis. Our study suggests 
that targeting EGFR may provide an effective therapeutic 
strategy for metastatic SACC with autocrine EREG and no 
genetic EGFR mutation.  
Figure 7: Targeting EGFR inhibits the lung metastasis of SACC in vivo. (A) SACC-LM cells treated with or without erlotinib 
(2 uM) for 72 hours were injected into the tail vein of nude mice. Histopathologic analysis shows small metastatic nodules in lung tissues. 
(B) Graphic representation of the area of lung metastases with mean ± SD; n = 5. (C–D) Patient survival obtained from publicly available 
microarray data was analyzed based on EREG mRNA expression level.
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MATERIALS AND METHODS
Cell cultures and reagents 
Human SACC cell lines SACC-83 and SACC-LM 
were obtained from Shanghai 9th People’s Hospital. Cells 
were cultured in RPMI-1640 (Gibco BRL, Grand Island, 
NY) with 10% fetal bovine serum (Gibco) and incubated 
in a humidified atmosphere of 95% air and 5% CO2 at 
37°C. Recombinant Human epiregulin was obtained from 
R & D Systems (Minneapolis, MN, USA). Antibodies 
against GAPDH were from Santa Cruz Biotechnology 
(Santa Cruz, CA). Antibodies for E-cadherin, N-cadherin, 
vimentin, Snail, Slug, p-EGFR, p-AKT, p-ERK, 
p-SATAT3, EGFR, AKT, Erk and STAT3 were from Cell 
Signaling Technology Inc. (Beverley, MA,). Antibodies for 
ZO-1 and EREG and normal goat IgG were from Abcam 
(Cambridge, MA). HRP-conjugated secondary antibodies 
were from eBioScience (San Diego, CA).
Western blotting
The experimental protocol was performed as 
described previously [49]. Cells were lysed with RIPA 
lysis buffer (Cell Signaling Technology). Cell lysates 
were separated by SDS-PAGE in a 10% acrylamide 
gel and transferred onto a nitrocellulose membrane for 
immunoblot analysis.
Immunofluorescence
The experimental protocol was performed as 
described previously [50]. Cultured cells rinsed three 
times with PBS and fixed with 3.7% formaldehyde 
were permeabilized with 0.1% Triton X-100. After 
blocking in 1% BSA for 1 hour, cells were incubated 
with the primary antibody in a moist, 4ºC chamber 
overnight, washed and then incubated for 1 hour with 
Alexa Fluor 488 (in the dark), or 594 donkey anti-
rabbit IgG antibody (Invitrogen, Grand Island, NY) 
at room temperature . Washed cells (PBS containing 
0.02% Tween 20), stained by mounting onto a slide 
with aqueous mounting medium containing 0.5 mg/ml 
40–6-diamidino-2-phenylindole, were examined with a 
fluorescence microscope.
Reverse transcriptase polymerase chain reaction 
(RT-PCR)
The experimental protocol was performed as 
described previously [51]. Total RNA samples were 
extracted with TriPure Isolation Reagent (Roche, 
Switzerland) and cDNA prepared from 1 mg of total 
RNA using the SuperScript III System (Invitrogen Life 
Technologies). The mRNAs levels were determined by 
RT-PCR, using the following primers:
EREG (F: 5′-ATCCTGGCATGTGCTAGGGT-3′ 
and R: 5′-GTGCTCCAGAGGTCAGCCAT -3′); HB-EGF 
(F:5′-CCACACCAAACAAGGAGGAG-3′and (F:5′-CCA 
GGAGGTCCGCATGCTCAC-3′and R:R:5′-ATGAGAA 
GCCCCACGATGAC -3′); TGF 5′-GAGTGCAGACCC 
GCCCGTGGC-3′); AREG (F:5′-AGGATCACAGCAGAC 
ATAAAG-3′and R: 5′-CCAAAACAAGACGGAAAGTG 
A-3′); EGF (F:5′-ATGTGTGCAGAGGGATACGC-3′and 
R: 5′-GGTGAGGAACAACCGCTACA-3′); GAPDH (F: 
5′-TCCACCACCCTGTTGCTGTA -3′ and R: 5′-ACCAC 
AGTCCATGCCATCAC -3′); Snail (F: 5′-CGCGCTCTTT 
CCTCGTCAG -3′ and R: 5′-TCCCAGATGAGCATTGG 
CAG-3′); Slug  (F: 5′- GAGCATTTGCAGACAGGTCA-3′ 
and R: 5′- CCTCATGTTTGTGCAGGAGA-3′).
Transwell and wound healing assay
The experimental protocol was performed as 
described previously [52]. For the migration assay, cells 
(5 × 105) were seeded onto the upper chamber in 200 µL 
of serum-free medium; the lower compartment was filled 
with 0.6 mL of DMEM media supplemented with 10% of 
FBS. After 24 h incubation, migrated cells on the lower 
surface of the filter were fixed and stained using 1% crystal 
violet; cells on the upper side were removed using a rubber 
scraper. Fluorescent images were obtained; reported data 
are counts of migrated cells with experiments performed 
in triplicate. The procedure used for invasion assay was 
similar to that of the cell migration assay, except that the 
transwell membrane was coated with Matrigel.
Experimental lung metastasis model
This study was approved by the ethics committee of 
our institution. The experimental protocol was performed 
as described previously [22]. Cells (1 × 106/0.2 ml) were 
injected into the tail vein of BALB/c nude mice. Animals were 
sacrificed after 5 weeks, and the metastatic tumors in the lung 
assessed. No mice showed notable toxic effects or body weight 
loss during the experiment. Visible lung metastatic nodules 
were counted macroscopically or in paraffin embedded sections 
stained with H & E. Data were analyzed using Student’s t test; a 
P value less than 0.05 was considered significant.
Statistical analysis
Data analysis used SPSS (Statistic Package for 
Social Sciences) 13.0 for Windows (SPSS Inc., Chicago, 
IL, USA). Unpaired Student’s t-tests or U-Mann Whitney 
tests determined statistical significance between groups 
with P values < 0.05 considered significant.
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